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Background: Pharmacological treatment of atrial fibrillation (AF) in horses can be challenging
because of low efficacy and adverse effects. Flecainide has been tested with variable efficacy.
Objective: To test whether the efficacy of flecainide is dependent on AF duration.
Animals: Nine Standardbred mares.
Methods: Factorial study design. All horses were instrumented with a pacemaker and assigned
to a control or an AF group. On day 0, all horses were in sinus rhythm and received 2 mg/kg fle-
cainide IV. Atrial fibrillation subsequently was induced in the AF group by pacemaker stimula-
tion. On days 3, 9, 27, and 55, flecainide was administered to all horses, regardless of heart
rhythm.
Results: All horses in AF cardioverted to sinus rhythm on days 3 and 9. On day 27, 5/6 horses
cardioverted, whereas only 2/6 cardioverted on day 55. The time from the start of flecainide
infusion to cardioversion (range, 3–185 min, log transformed) showed linear correlation with
the cumulative duration of AF (r2 = .80, P < .0001). Flecainide induced abnormal QRS com-
plexes in 4/6 AF horses and 1/3 controls. A positive correlation was found between heart rate
before flecainide infusion and number of abnormal QRS complexes (0.14, P < .05). One horse
suffered from cardiac arrest and died after flecainide infusion.
Conclusions and Clinical Importance: Flecainide is effective for cardioversion of short-term
induced AF, but the effect decreases with AF duration. Controlling heart rate may minimize
adverse effects caused by flecainide, but the drug should be used with great caution.
KEYWORDS
arrhythmia, atria, cardioversion, electrocardiography, heart, wide QRS tachycardia
1 | INTRODUCTION
Atrial fibrillation (AF) is the most common pathological arrhythmia in
horses. The arrhythmia may lead to decreased performance and cause
safety issues for the rider or driver.1 Atrial fibrillation leads to
electrical, contractile, and structural remodeling of the atria, making
successful cardioversion more difficult to achieve with increased AF
duration.2 It is therefore important to know the duration of AF when
choosing a treatment strategy for the horse.3 Cardioversion of AF can
be performed pharmacologically with quinidine, which has an efficacy
of about 85% in horses with no underlying cardiac disease.3 However,
this treatment frequently results in adverse cardiac or noncardiac
reactions, and treatment may need to be terminated before
Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; bpm, beats per minute;
BW, body weight; HR, heart rate; HRrest, resting heart rate; JTc, corrected JT
interval; QTc, corrected QT interval
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cardioversion. The search for alternative solutions is therefore ongo-
ing, and antiarrhythmic drugs tested in horses include flecainide,4–6
amiodarone,7,8 propafenone,9 sotalol,10 NS8593,11 dofetilide, and
ranolazine.12 Some of these drugs have only been tested in an experi-
mental setting,11,12 whereas others also have shown some effect in
naturally occurring AF.7,8
Flecainide is a class Ic antiarrhythmic drug that blocks sodium cur-
rents and thereby slows intramyocardial conduction. Electrophysiolog-
ical studies in horses have shown an increase in the AF cycle length
preceding cardioversion, but no effect on the atrial effective refrac-
tory period.4,6 Studies on flecainide for cardioversion of AF have pro-
vided conflicting results. High efficacy was seen in horses with
experimentally induced AF,4,5 but flecainide was only effective in 1 of
10 horses with naturally occurring AF and in 41% of horses with
recent-onset AF.6,13 Reported adverse effects include agitation, rest-
lessness, neck sweating, decreased borborygmi5,14 and several cases
of ventricular proarrhythmia and sudden death.6,15–17 Flecainide
resulted in widening of the QRS complex4,6,15 and 1 study also
reported prolongation of the QT interval.4 Flecainide is widely used
for cardioversion and the maintenance of sinus rhythm in humans suf-
fering from AF. Guidelines for selecting treatments in human AF
patients indicate that flecainide can be used for those with recent-
onset AF and no other major cardiac abnormalities such as hyperten-
sion, ischemia, or impaired left ventricular function.18,19
We hypothesized that the antiarrhythmic effects of flecainide in
horses are dependent on the duration of AF. Information on the maxi-
mum duration of AF allowing for cardioversion with flecainide would
help to guide clinicians considering flecainide as a treatment option.
Therefore, the aim of our study was to test flecainide treatment in
horses with induced AF at selected time points and different AF
durations.
2 | MATERIALS AND METHODS
2.1 | Horses
Nine Standardbred mares were studied; 6 in an AF group (horses 1–6)
and 3 in a group of sham-operated time-matched controls (horses
7–9). The AF group had a mean age of 10  3 years (range,
5-14 years) and mean body weight (BW) of 479  49 kg (range,
408-572 kg) at inclusion in the study, and the control group had a
mean age of 12  6 years (range, 4-17 years) and mean BW of
466  32 kg (range, 423-498 kg). Baseline, routine venous blood ana-
lyses including hematology and serum biochemistry profiles were per-
formed for all horses and all results were within normal limits. The
horses included in the study had no signs of cardiovascular disease
after clinical examination, thorough cardiac auscultation, 12-hour Hol-
ter ECG (KRUTECH Televet, Kruuse A/S, Maarslev, Denmark) and
routine echocardiographic examination (2D, M-mode and color flow
Doppler)20 with a portable ultrasound unit with a phased array trans-
ducer (Vivid I and 3S Phased Array transducer, GE Healthcare, Horten,
Norway). The present study was part of a larger study on chronic AF
development in horses, and the same horses were therefore included
in other studies.
The study was approved by the local ethical committee at the
Department of Veterinary Clinical Sciences, University of Copenhagen
and The Danish Animal Experiments Inspectorate (license number
2015-15-0201-00693), and was performed in accordance with the
European Commission Directive 86/609/EEC.
2.2 | Pacemaker implantation
All horses (both controls and AF group) had a dual-chamber pace-
maker implanted (Assurity MRI 2272, St. Jude Medical, St. Paul, MN)
with 2 bipolar leads (Tendril STS Pacing Leads 100 cm, St. Jude Medi-
cal, St. Paul, MN) in the right atrium, by a modified technique
described previously.43 In brief, the horses were restrained in a stock,
sedated with 0.01 mg/kg BW detomidine (Domosedan, Orion Pharma
Animal Health, Copenhagen, Denmark) and 0.01 mg/kg BW butor-
phanol (Torbugesic, Orion Pharma Animal Health, Copenhagen, Den-
mark) followed by a constant-rate infusion of 180–360 mL/h of
1.0 mg/mL xylazine (Xysol, ScanVet Animal Health A/S, Fredensborg,
Denmark). A modified base-apex ECG was recorded throughout the
procedure. The area of the right lateral pectoral groove was locally
anesthetized and an incision of 6–8 cm was made followed by blunt
preparation of the cephalic vein. The pacemaker leads were intro-
duced to the right atrium through a venotomy in the cephalic vein,
and their placement was guided by stimulation via the programmer
(Merlin Patient Care System Programmer, St. Jude Medical, St. Paul,
MN) while advancing the leads until atrial capture. Once the leads had
been fixed with a screw-in technique at a position where atrial cap-
ture was consistent, the stimulation threshold and lead impedance
were determined by the programmer. The leads were secured with a
ligature around the cephalic vein and connected to the pacemaker.
The pacemaker was fixed to the underlying tissue in a SC pocket distal
to the incision, and the incision was closed in 3 layers. The operation
time was between 60 and 150 min. All horses were treated with anti-
biotic and nonsteroidal anti-inflammatory therapy for the next 3 days.
The animals were tied to prohibit lying down or rolling for 1 week
after the procedure, and the experiments began after a recovery
period of 3 weeks.
2.3 | Study protocol
An overview of the study protocol is presented in Figure 1. The study
was performed over a period of 55 days. All horses (both the AF and
control groups) had flecainide (Tambocor, Meda A/S, Allerød, Den-
mark; 2 mg/kg, rate 0.2 mg/kg/min) administered IV while in sinus
rhythm, which allowed performance of ECG analyses (see below) after
flecainide infusion in the AF group before induction of AF. Induction
of AF with burst- and high-rate pacing was initiated in the AF group
6- 8 hours after baseline flecainide administration, and continued until
AF was self-sustained or the next flecainide administration on days
3, 9, 27, and 55 by the same protocol as described above. No AF
induction was performed in the control group. Pacing was stopped
30 minutes before flecainide infusion for horses in the AF group with-
out self-sustained AF. If cardioversion was successful, AF induction
was restarted approximately 6 hours later and continued until self-
sustained AF was reached or the next flecainide testing was
CARSTENSEN ET AL. 1709
scheduled. Flecainide administration was performed between 9 AM
and 12 PM on all procedure days. In addition, cardioversion of AF was
attempted in horse 1 on day 59 with 2 doses of flecainide. The second
dose of flecainide was identical to the first and was infused 10 min
after the first infusion ended. Because of an episode of colic, flecai-
nide was not administered on day 3 in 1 control horse (horse 9).
2.4 | AF induction
A pacemaker was used to induce AF by burst-pacing (20 seconds,
10 Hz, pulse amplitude 7.5 mV, pulse width 1.5 ms) in the right atrium.
Burst-pacing was limited to strains of 20 seconds by the pacemaker.
These strains were delivered on a daily basis (1-8 hours per horse)
until AF was self-sustained. In between burst-pacing sessions, the
pacemaker was set to stimulate in an inhibitory mode with an atrial
rate of 170 per minute (pulse amplitude 2.5 mV, pulse width 0.4 ms)
from each lead, leaving the horse with an atrial paced rhythm of
340 per minute. This practice ensured that the atria were not left in
sinus rhythm but constantly were subjected to a fast rate throughout
the study. Self-sustained AF was defined as AF of >10 minutes dura-
tion without stimulation from the pacemaker. When self-sustained AF
had reached a duration of more than 24 hours, the pacemaker was
switched off. The horses were subsequently auscultated daily to
confirm AF.
2.5 | ECG recordings
Electrocardiograms were recorded throughout each procedure day
with a Holter unit with 2 separate channels and bipolar leads as previ-
ously described.4 Additionally ECGs were recorded between
procedure days to assess heart rhythm if auscultation was not feasi-
ble. During AF induction, ECG was continuously recorded. If a horse
was in self-sustained AF after a burst-pacing session, the Holter unit
remained on to assess if and when cardioversion occurred, but if AF
was not self-sustained and the horse was left with an atrial paced
rhythm over night, the Holter unit was removed until burst-pacing
was initiated again. The cumulative duration of AF (including all
periods of self-sustained AF) for each horse was assessed by analyzing
the ECG recordings and documented auscultations. Burst-pacing,
pacemaker activity, and time periods of unknown activity in the atria
were not included.
Heart rate at rest (HRrest) was measured for all horses before day
0 on surface ECGs obtained between 8 PM and 6 AM, because the
horses were undisturbed in their stables during this period. Three
time-points at which the heart rate (HR) was low and stable were cho-
sen from the heart rate view (Televet) and HR was measured as an
average of 10 beats for each time point. The HRrest was calculated
again in the AF group once AF was self-sustained, and on day 27 or
55 of the study (minimum, 11 hours after flecainide infusion) for the
control group. The mean HR before flecainide infusion was calculated
for all horses by averaging all RR intervals for 30 minutes before the
start of infusion.
The QRS durations and QT intervals were manually analyzed in
lead II at 4 different time points: before, 1 minute after, 30 minutes
after, and 60 minutes after the end of flecainide infusion. Five
repeated measurements were performed at each time point. The QT
measurements were corrected according to HR with a piecewise lin-
ear regression model,21 and JTc intervals were calculated as QTc
minus QRS. To identify abnormal QRS complexes, ECGs were manu-
ally analyzed 30 minutes before, during and 30 minutes after the end
FIGURE 1 Overview of the study protocol. The flowchart shows the order of interventions for the horses in the two groups. AF = atrial
fibrillation
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of flecainide infusion. The QRS complexes were classified as abnormal
if they had bizarre morphology or the R-on-T phenomenon was pre-
sent. Occurrence was characterized as either single or coupled abnor-
mal QRS complexes or episodes of consecutive abnormal QRS
complexes (≥3 abnormal complexes sequentially).
2.6 | Statistical analysis
Data are presented as mean  SD when normally distributed and
without SD when the distribution was not normal. The cumulative
duration of AF for responders (cardioversion to sinus rhythm after fle-
cainide infusion) and nonresponders (no cardioversion) was compared
using an unpaired t test. The time (min) to cardioversion was log trans-
formed before performing linear regression of the time to cardiover-
sion as a function of the cumulative AF duration (in days). We
compared the mean HRrest before and after the start of the study in
both the AF group and the controls by paired t tests (GraphPad Prism
5 software, GraphPad Software, San Diego, CA). A linear mixed model
including heart rhythm (AF or sinus rhythm) and study day was used
to test the correlation between number of abnormal QRS complexes
after flecainide infusion and mean HR before infusion. Analyses of
QRS duration, JTc and QTc also were performed by a linear mixed
model (R 3.3.1 software, The R Foundation for Statistical Computing,
Vienna, Austria). The QRS duration and QTc after flecainide infusion
were compared for the AF group and the controls by an unpaired
t test. P ≤ .05 was considered to be significant.
3 | RESULTS
On day 3, only 1 horse had self-sustained AF and this horse cardio-
verted 3.0 minutes after flecainide infusion began. The cumulative
duration of AF up to day 3 was 0.4  0.5 days (range, 0.1-1.3 days).
On day 9, 5 of 6 horses had self-sustained AF and all 5 horses cardio-
verted to sinus rhythm within 8.8 minutes (range, 6.0-12.0 minutes) of
the start of flecainide infusion. The cumulative duration of AF up to
day 9 was 1.4  0.9 days (range, 0.5-2.8 days). All horses were in self-
sustained AF on day 27 and day 55. Five of 6 horses cardioverted on
day 27 within 25.0 minutes (range, 4.0-62.0 minutes), whereas 2 of
6 cardioverted on day 55 at 96.0 and 185.0 minutes, respectively. The
cumulative duration of AF up to day 27 was 11.25  6.8 days (range,
0.8-17.3 days) for the responders, with the nonresponder exhibiting
the longest AF duration of 18.3 days. Before day 55, the cumulative
duration of AF was 37.4  11.8 days (range, 15.2-46.3 days) for all
paced horses. The AF duration for the nonresponders and responders
up to day 55 was 37.9  15.1 and 36.4  2.0 days, respectively
(P = .90). Linear regression with log transformed time to cardioversion
as the response showed an effect size (slope) of 0.04 (95% confidence
interval [CI] 0.02, 0.05) for cumulative AF duration, and an overall
coefficient of determination (r2) of .80 (P < .0001, Figure 2).
The ECG showed that AF slowed during treatment into more dis-
tinct, coarse fibrillatory waves in the time preceding cardioversion in
the majority of horses. In horse 2 and horse 5, AF was terminated by
flecainide on day 55, and this coarse AF state lasted >1 hour and
2.5 hours before cardioversion, respectively. More than 30 minutes of
coarse AF also preceded cardioversion on day 27 in horse 5. The tran-
sition from AF to coarse AF is illustrated in Figure 3. Coarse AF was
not seen in procedures where AF was not cardioverted.
The mean HRrest was significantly increased after AF induction
compared to before induction in the AF group: ΔHRrest = 12  9
beats per minute (bpm); range, 4-26 bpm, P < .001 (Figure 4). The in-
crease was largely attributed to 2 horses (horses 1 and 4) with a very
FIGURE 2 Time to cardioversion as a function of the cumulative
duration of atrial fibrillation. Time to cardioversion (in min) was log
transformed and plotted against the cumulative duration of self-
sustained atrial fibrillation (AF) for all flecainide infusions in horses
with AF. Linear regression revealed a slope of 0.04 (95% CI 0.02,
0.05) with a coefficient of determination of 0.80
FIGURE 3 Transition from fine to coarse AF. The ECG sections (lead II) should be viewed in succession. The ECG was recorded 12 min after the
end of flecainide infusion on day 27. It is evident that the atrial fibrillation becomes coarse, with distinct fibrillatory waves. The atrial rate is
170/min (352 ms interval) in the last part of the ECG. The horse cardioverts to sinus rhythm 40 min later
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high ΔHRrest: 17 and 26 bpm, respectively. An ECG was not available
for horse 3 in AF in the specified time period (8 PM-6 AM) and this
horse was not included in the analysis.
The ECG parameters QRS duration and QTc were significantly
prolonged by flecainide infusion compared to baseline measurements
(P < .001) in the first hour after infusion, with the largest prolongation
measured immediately after the end of flecainide infusion (“0 min”,
Figure 5). The difference between QTc and QRS, represented by JTc,
also was prolonged at all time points after flecainide infusion
(P < .001). The QRS duration after flecainide infusion was
125  18 ms in the AF group and 114  11 ms in the control group
(P < .001). The QTc was 477 38 ms and 481 32 ms in the AF and
control groups, respectively (P = .223).
None of the horses experienced any noncardiac adverse reactions
to flecainide, but adverse cardiac reactions were seen in several
horses and 1 horse suffered from sudden cardiac death after 2 con-
secutive flecainide infusions. Table 1 summarizes the number of ani-
mals that experienced abnormal QRS complexes 30 minutes before,
during and 30 minutes after flecainide infusion. Abnormal QRS com-
plexes were observed in 4 of the horses in the AF group (horses 1-4),
with horses 1 and 4 also suffering episodes of consecutive abnormal
QRS complexes. All 4 horses experienced abnormal QRS complexes
both with and without the influence of flecainide. Only 1 abnormal
complex was found after flecainide infusion in the control group.
Examples of both single abnormal QRS complexes and an episode of
consecutive abnormal QRS complexes after infusion of flecainide are
shown in Figure 6. Detomidine (5 mg) was administered to 2 of the
horses with consecutive abnormal QRS complexes (Table 1) in an
attempt to stop the tachycardia. No further subsequent abnormal
QRS complexes were identified. A correlation was found between the
mean HR for the 30 minutes preceding the start of flecainide infusion
and the number of abnormal QRS complexes after the start of infusion
(effect size = 0.14; 95% CI, 0.0047, 0.2766; P < .05).
One dose of flecainide was unable to cardiovert horse 1 on day
55, and thus 2 doses were used on day 59 (10 minutes between
doses). No abnormal QRS complexes were encountered during infu-
sion of the first dose or in the 10 minutes after infusion. However,
the horse developed several runs of torsades-like ventricular tachycar-
dia with preceding short-long-short coupling initiation before devel-
oping ventricular fibrillation and eventually cardiac arrest during
administration of the second dose. Flecainide infusion was stopped
when the ventricular tachycardia developed but no other drugs were
administered to this horse because of concerns about personnel
safety in establishing IV access. Figure 7A displays the last 6 minutes
of ECG recorded from this horse, and shows that the QRS complex
gradually became wider. Simultaneously, AF became coarser, as illus-
trated by the appearance of distinct fibrillatory waves, similar to those
observed in the horses before cardioversion to sinus rhythm
(Figure 7B).
4 | DISCUSSION
Ours is the first systematic study to investigate the time-dependent
ability of flecainide to terminate AF in horses. The results indicate that
flecainide could be considered for the cardioversion of short-duration
AF, but also that great caution should be used because the potential
adverse effects include sudden death. The HRrest during AF was mark-
edly increased for some horses. A correlation was found between HR
and the number of abnormal QRS complexes in the ventricles after
flecainide infusion. Furthermore, the horses experiencing episodes of
consecutive abnormal QRS complexes were those with the highest
HRrest. Abnormal QRS complexes were observed in the AF group
before flecainide infusion, and to a greater extent after flecainide infu-
sion, confirming the ventricular proarrhythmicity of flecainide.
FIGURE 4 Mean heart rate at rest.Mean heart rate at rest (HRrest)
for the individual horses measured on surface baseline ECG “start”
and after pacing “end” in control and AF groups. The line and error
bars reflect the mean  SD. *** = P < 0.001
FIGURE 5 Ventricular effects of flecainide administration. QRS duration (A) and corrected QT intervals (QTc) (B) before and after flecainide
treatment in all horses (n = 9) presented in box plots with whiskers from minimum to maximum values. # Represents the significance level of the
comparison between the time points after flecainide infusion and the baseline (### = P < 0.001). * = P < 0.05, *** = P < 0.001
1712 CARSTENSEN ET AL.
With flecainide use, all horses in AF cardioverted on days 3 and
9, and 5 of 6 horses cardioverted on day 27, whereas only 2 of
6 horses cardioverted on day 55 after the start of AF induction. These
results correlate with those of previous studies, which found flecai-
nide to be effective in induced AF of very short duration
(15 minutes),4,5 but not in naturally occurring chronic AF.6,14 In 1
study, naturally occurring AF with a duration of 12 days could be ter-
minated by flecainide infusion,6 and in another study, flecainide was
effective in 2 cases of naturally occurring AF.5 Furthermore, flecainide
was reported to cardiovert 12 of 29 horses with recent-onset AF.13
These findings suggest that the effects seen with flecainide are not
restricted to experimentally induced AF. Because the horses in our
study did not develop AF naturally, they may lack some of the cardio-
vascular factors leading to AF. A certain degree of remodeling is nec-
essary for AF to be self-sustained, creating the substrate for the
maintenance of AF.22 The cumulative duration of AF in this protocol
referred only to self-sustained AF, implying that remodeling must have
been present, mimicking naturally occurring AF. The remodeling we
TABLE 1 Prevalence of abnormal QRS complexes and ventricular tachycardia before and after flecainide infusion









Day 0 Before treatment 1 (1) – – –
Flecainide – – – –
Day 3 Before treatment 1 (20) – – –
Flecainide – – – –
Day 9 Before treatment 2 (6/12*) – – –
Flecainide 3 (2/3/6) – 1 (1) –
Day 27 Before treatment 1 (1) – – –
Flecainide 4 (1/3/7*/12*) 2 (1/4#) – –
Day 55 Before treatment 2 (2/8*) 1 (1) – –
Flecainide 2 (10*/16*) 2 (1/1#) – –
Number of horses experiencing single or coupled abnormal QRS complexes and number of horses experiencing episodes of consecutive abnormal QRS
complexes in separate columns. The number of abnormal complexes and episodes of consecutive abnormal complexes are specified in brackets with the
number for each horse separated by “/”. * indicates that some of the abnormal QRS complexes are coupled. # indicates that detomidine was administered.
AF = atrial fibrillation; Before = 30 min before flecainide infusion; Flecainide = during and 30 min after flecainide infusion.
FIGURE 6 Abnormal ECG findings after flecainide infusion. Single abnormal QRS complexes (A) and an episode of consecutive abnormal QRS
complexes (B). The QRS complexes were classified as abnormal because they display the R-on-T phenomenon. All ECG examples are lead II.
* indicates abnormal complexes
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expect to be present is electrical and contractile remodeling which
was seen in horses after 4 and 12 hours of induced AF, respectively.15
Furthermore, structural remodeling has been found in goats after
1 week of pacing-induced AF, which likely also occurred in these
horses.23 The time from the start of flecainide infusion to cardiover-
sion was correlated with the cumulative duration of AF. This finding
demonstrates the process of remodeling and the importance of know-
ing AF duration when selecting a therapeutic regimen.
Comparing cardioversion and the cumulative duration of self-
sustained AF, flecainide appears to be a plausible treatment option in
AF with a duration <2 weeks, provided great caution is taken because
the drug may cause severe adverse effects, including sudden death.
The horse that did not cardiovert on day 27 also had the longest dura-
tion of self-sustained AF (18.3 days). In human medicine, flecainide
primarily is used for acute onset AF (<48 hours), and its reported effi-
cacy is between 52 and 95%.24 A consensus statement indicated that
in horses with AF, cardioversion should not be attempted before
24-48 hours of documented AF because of the chance of spontane-
ous cardioversion.1 In humans, lack of early intervention may, how-
ever, cause recurrence of AF in the long term, and early cardioversion
may lower the risk of relapse.25 This can be explained by the electro-
physiological remodeling that occurs within a few hours of AF, which
facilitates persistence of the arrhythmia.15,22
Both horses that responded to flecainide on day 55 showed a
change from fine to coarse AF before cardioversion to sinus rhythm.
The coarse AF likely represents an increase in the atrial fibrillation
cycle length as seen previously after flecainide infusion in horses.4,26
In humans, conversion from AF to atrial flutter (AFL) with class Ic anti-
arrhythmic compounds is a known complication. By slowing down
conduction velocity, flecainide can transform the unorganized multiple
microreentry circuits in the atria during AF into a single organized
macroreentry circuit that is seen as AFL on the ECG.27 Because class
Ic antiarrhythmic drugs do not slow atrioventricular conduction, a risk
of 1:1 atrioventricular conduction with wide QRS tachycardia
exists.28,29 In these horses, the coarse AF terminated without further
treatment and no 1:1 conduction through the atrioventricular node
was observed. Pharmacological cardioversion of AFL tends to be diffi-
cult30,31 and AFL is not well-characterized in horses. These consider-
ations led us to avoid defining coarse AF as AFL.
Whether abnormal QRS complexes such as those encountered in
our study are caused by re-entry phenomena in the ventricle or rapid
atrioventricular conduction must be elucidated further. In humans,
ventricular tachycardia often is caused by re-entry involving some
degree of damage in the cardiac tissue, or triggered activity after
delayed repolarization.32 Because both single and consecutive abnor-
mal QRS complexes occurred in the AF group without the influence of
flecainide and ventricular damage because of AF seems improbable,
aberrant conduction appears to be the most likely cause. However,
because we were unable to determine the origin of the abnormal
complexes, no classification was made.
FIGURE 7 Electrocardiogram obtained during flecainide infusion resulting in cardiac arrest. The ECG (lead II) is from a horse receiving a second
dose of flecainide in an attempt to cardiovert atrial fibrillation with a duration of 59 days. After several episodes of torsades-like ventricular
tachycardia with preceding short-long-short coupling initiation (*) the horse develops ventricular fibrillation (VFib). A) Is an overview of the last
6 min leading up to cardiac arrest and B) is a section of the ECG where distinct fibrillatory waves appear at a rate of 163/min (368 ms interval)
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Flecainide infusion resulted in more abnormal QRS complexes
than were encountered before drug infusion, and the drug appears to
pose a risk. The number of abnormal QRS complexes observed after
the start of flecainide infusion was weakly correlated with HR before
infusion. Resting tachycardia in AF usually occurs because of sympa-
thetic nervous stimulation or underlying cardiac disease.1 All horses
had healthy hearts upon inclusion in the study, and no horse showed
signs of heart failure during the experiments. Sympathetic stimulation
because of stress or pain from the experimental setup could be a pos-
sible explanation for the increase in HRrest, but the sham-operated
control animals did not experience an increase in HRrest, despite
being subjected to the same procedures as the AF horses. The
increase in sympathetic stimulation could have had a larger effect on
the atrioventricular node compared to the sinoatrial node and conse-
quently only increased HRrest in the AF group. Alternatively, the
increase in sympathetic nervous stimulation may be unrelated to the
experimental design and caused by stress or pain because of the
presence of AF.
Fast atrial rhythm (eg, AF with a slow cycle length or AFL) in com-
bination with an atrioventricular node capable of conducting these
high rates into the ventricles poses a risk for severe, life-threatening
arrhythmias.33 The incidence consequently is increased by the pres-
ence of adrenergic stimulation,34 and the general advice is to adminis-
ter atrioventricular nodal blocking drugs such as β-blockers or
nondihydropyridine calcium channel antagonists along with class Ic
antiarrhythmic drugs in humans.19 Flecainide has a high affinity for
sodium channels in the open state and the effect is therefore strongly
use dependent.35 Flecainide also has some blocking effects on potas-
sium channels, but this effect is decreased at higher HRs (reverse use
dependency).36 Consequently, increased HR will result in a greater
decrease in ventricular conduction velocity by flecainide and could
lead to increased risk of re-entry arrhythmias.37 This substantiates the
recommendation of concurrent rate control during flecainide
treatment.
A wide QRS tachycardia after flecainide administration previously
has been reported in horses, and a slowing of the ventricular rate with
the alpha 2-adrenoreceptor agonist detomidine was able to terminate
the dysrhythmia.6 Detomidine administration causes bradycardia by
inhibiting the sympathetic nervous system and increasing vagal tone
as a response from the baroreceptors to hypertension induced by ini-
tial alpha-2β adrenoreceptor stimulation.38,39 In accordance with this
effect, no further abnormal QRS complexes were seen in the 2 horses
in which detomidine was infused in our study. No rate-controlling
drugs were administered with flecainide to the horse that received
the double dose and we therefore do not know whether slowing the
atrioventricular conduction would have abrogated the occurrence of
ventricular fibrillation. Flecainide also can cause monomorphic ventric-
ular tachycardia in humans and it may be challenging to distinguish
between this rhythm and 1:1 conduction of AFL.33 However, based
on the successful use of detomidine in preventing further consecutive
abnormal QRS complexes in these horses, it seems likely that what we
observed was 1:1 conduction of the supraventricular tachycardia.
These findings strongly indicate that flecainide should be used in con-
junction with a rate-controlling drug in horses, but additional investi-
gations are warranted.
Flecainide infusion prolonged the QRS duration and QTc inter-
val. The QRS duration reflects ventricular conduction velocity, and
prolongation was expected and corresponded with the findings from
previous studies.4–6 After flecainide infusion, the QRS duration was
longer in the AF horses compared to the controls and one could
speculate that this could have contributed to the occurrence of
abnormal QRS complexes. As seen in Table 1, these primarily
occurred when the horses were in AF. Prolongation of the QTc
interval is not consistently reported in horses. One study found a
prolongation only at higher doses of flecainide,5 whereas a second
study found prolongations similar to what we observed.4 We could
show that the ventricular repolarization was prolonged indepen-
dently from QRS prolongation by calculating the JTc interval. This
prolongation is linked to the risk of torsades de pointes ventricular
tachycardia in humans.40 However, flecainide does not induce JTc
prolongation in humans, and flecainide-induced torsades de pointes
ventricular tachycardia is rare.41,42 A JTc prolongation after flecai-
nide infusion also was found in another study,4 but the association
between this prolongation and torsades de pointes ventricular
tachycardia in horses remains to be proven.
Spontaneous cardioversion rates after experimentally induced
AF of hours or days in duration is difficult to predict because limited
information is available in the literature. One study found that 4/6
horses subjected to pacing-induced AF of 7 day’s duration cardio-
verted spontaneously within 3 days of no pacing.15 Our study did
not include any control horses receiving saline, which would have
allowed us to study spontaneous cardioversion. This design feature
is a limitation of this study as we are unable to tell whether sponta-
neous cardioversion may have occurred on the specified procedure
days. However, the fact that most AF episodes were self-sustained
for hours to weeks before treatment, and cardioversion was
achieved within a short time of flecainide infusion, strongly indicates
that cardioversion was induced by the antiarrhythmic effects of
flecainide.
The ECGs were analyzed no more than 30 minutes before and
60 minutes after flecainide infusion. Furthermore, ECG recordings
were obtained mainly on procedure days and during AF induction.
Additional uninterrupted ECG recordings or a larger study population
could have provided a larger set of data and made comparisons more
valid. Statistical significance should be evaluated with the number of
animals studied in mind.
In conclusion, the efficacy of flecainide for AF cardioversion in
horses with experimentally induced AF decreases with the duration of
AF. Increased HR was correlated with the number of abnormal ven-
tricular complexes after flecainide infusion, and further investigation
into rate-controlling drugs administered in conjunction with flecainide
is warranted. Until further studies are available, flecainide should be
used with great caution in horses because the drug can lead to severe
proarrhythmic events and sudden death.
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